Respiratory News and Research

RSS

Covidien, Somanetics sign definitive merger agreement

Covidien plc and Somanetics Corporation today announced that they have signed a definitive merger agreement under which Covidien will acquire all of the outstanding shares of Somanetics Corporation for $25.00 per share in cash, for a total of $250 million, net of cash acquired.

16 Jun 2010

University of Montreal scientists discover free radical mechanism to viral invasion

Canadian researchers have discovered a new way the body combats respiratory viral infections. In the prestigious journal PLoS Pathogens, scientists from the University of Montreal and the University of Montreal Hospital Research Center explain how the NOX2 molecule, an enzyme that generates a burst of highly reactive oxygen derivatives (or free radicals), activates defense genes and molecules when viruses invade lung cells.

16 Jun 2010

Study examines survival rates of CF patients with MRSA

A team of researchers led by Elliott Dasenbrook, MD, MHS, Assistant Professor of Medicine and Pediatrics at Case Western Reserve University School of Medicine and Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center's Rainbow Babies & Children's Hospital today published the findings from a major study about cystic fibrosis survival rates in the June 16 issue of JAMA.

16 Jun 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Researchers discover how bacteria boost the immune system

Scientists have long known that certain types of bacteria boost the immune system. Now, Loyola University Health System researchers have discovered how bacteria perform this essential task.

15 Jun 2010

Increased risk of cardiovascular problems can affect people with mild to moderate SDB: Research

Doctors have long known that snoring is hazardous to health for a number of reasons. In addition to restless nights and increased daytime sleepiness, sleep-disordered breathing has a series of associated health problems, including increased risk of cardiovascular disease. While it is not always clear what the association between SDB and a given health problem is, new research exposes that at least one factor may help to explain the increased risk of cardiovascular problems that affects even people with mild to moderate SDB.

15 Jun 2010

Researchers establish link between air pollution and SDB

Researchers from Brigham and Women's Hospital and the Harvard School of Public Health have established the first link between air pollution and sleep-disordered breathing, a known cause of cardiovascular diseases.

15 Jun 2010

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Ingen Technologies, Inc., a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.

14 Jun 2010

Study evaluates correlation between EverOn system and detection of patient deterioration in hospitals

EarlySense, developer of the EverOn contact-free, patient supervision system for hospital and post acute care, announced today the results of a multicenter study conducted at several hospitals in the United States and Israel. The data were recently made public by Drs. Eyal Zimlichman, Martine Szyper-Kravitz, Howard Amital, and Yehuda Shoenfeld at the American Thoracic Society Conference in New Orleans in a presentation titled, Recognizing Specific Respiratory Patterns Preceding in Hospital Clinical Deterioration, a Multicenter Study.

14 Jun 2010

Discovery Labs secures new Committed Equity Financing Facility with Kingsbridge

Discovery Laboratories, Inc., announced today that it has secured a new Committed Equity Financing Facility (2010 CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge has committed to provide up to $35 million of capital over a three-year period through the purchase of up to approximately 31.6 million newly-issued shares of Discovery Labs' common stock.

14 Jun 2010

U.S. judge approves $712.5 million settlement for 9/11 responders' health problems

"Thousands of first responders, firefighters and construction workers sickened by toxic rubble at Ground Zero could share in a settlement of up to $712.5 million announced Thursday, three months after a federal judge said a previous deal did not pay victims enough. U.S. District Court Judge Alvin Hellerstein gave preliminary approval to the settlement of a 7-year-old lawsuit against the city by nearly 10,000 people who suffered illnesses from exposure to dust and debris at the World Trade Center site after the Sept. 11 attacks."

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

BIOTECanada congratulates CPHA on 100 years of leadership in public health

As a community partner of the Canadian Public Health Association, BIOTECanada, on behalf of Canada's biotechnology industry, congratulates the CPHA on 100 years of leadership in public health.

11 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.

11 Jun 2010

$125M added to plaintiffs' compensation in WTC site operations

The WTC Captive Insurance Company, the City of New York, the contractors the City hired, their subcontractors, and attorneys for over 10,000 plaintiffs alleging injuries from the rescue, recovery and debris removal operations at the World Trade Center site operations after 9/11 today announced amendments to a March 11, 2010 settlement of those claims.

11 Jun 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

RXi announces new RNAi therapeutic strategy at Jefferies 2010 Global Life Sciences Conference

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the company's new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences Conference.

11 Jun 2010

Sharron Davies unveils new Nottingham Respiratory BRU Clinical Trials Unit

Olympic swimmer and television personality Sharron Davies MBE was in Nottingham this week to open a new clinical trials unit that will take treatments for respiratory illnesses such as asthma from laboratory bench to bedside.

11 Jun 2010

New study finds propofol poses low risk for children undergoing research-driven imaging studies

A new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

10 Jun 2010

Respiratory News and Research

Covidien, Somanetics sign definitive merger agreement

University of Montreal scientists discover free radical mechanism to viral invasion

Study examines survival rates of CF patients with MRSA

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Researchers discover how bacteria boost the immune system

Increased risk of cardiovascular problems can affect people with mild to moderate SDB: Research

Researchers establish link between air pollution and SDB

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Study evaluates correlation between EverOn system and detection of patient deterioration in hospitals

Discovery Labs secures new Committed Equity Financing Facility with Kingsbridge

U.S. judge approves $712.5 million settlement for 9/11 responders' health problems

Chiasma successfully completes Phase I clinical study of Octreolin

BIOTECanada congratulates CPHA on 100 years of leadership in public health

Phase II study results of riociguat for CTEPH and PAH published online

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

$125M added to plaintiffs' compensation in WTC site operations

Investment report on Novavax

RXi announces new RNAi therapeutic strategy at Jefferies 2010 Global Life Sciences Conference

Sharron Davies unveils new Nottingham Respiratory BRU Clinical Trials Unit

New study finds propofol poses low risk for children undergoing research-driven imaging studies

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News